Heron’s HTX-011 nabs accelerated review in Canada for postoperative pain

Under Priority Review status, Health Canada has accepted Heron Therapeutics’ (NASDAQ:HRTX) New Drug Submission (NDS) for HTX-011 for the management of postoperative pain.

Priority Review status provides an accelerated 6-month review target for the NDS.

HTX-011, an investigational agent, is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam.

https://seekingalpha.com/news/3523281-herons-htxminus-011-nabs-accelerated-review-in-canada-for-management-of-postoperative-pain